Literature DB >> 16219636

Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations.

Il-Jin Kim1, Hio Chung Kang, Sang-Geun Jang, Kun Kim, Sun-A Ahn, Hyun-Ju Yoon, Sang Nam Yoon, Jae-Gahb Park.   

Abstract

Various types of human cancers harbor BRAF somatic mutations, leading researchers to seek molecular targets for BRAF inhibitors. A mutually exclusive relationship has been observed between the BRAF-V600E mutation and K-ras mutations, suggesting that the BRAF-V600E mutation may differ from the other BRAF mutant types. Here, we used microarray analysis to examine differences between the BRAF and K-ras mutant colorectal samples and within the BRAF group (V600E versus non-V600E), in the hope that the identified gene sets could form the basis for new target development. Eleven colorectal cancers (CRCs) with BRAF mutations and nine with K-ras mutations were examined by high-density microarray analysis. We also tested whether other significant genetic or clinical status involved in CRC development, such as APC and TP53 mutations, MSI and TNM-Duke's staging, were related with the observed BRAF- or K-ras associated expression profiles. Unsupervised two-way hierarchical clustering and multidimensional scaling revealed that the differentially expressed genes clustered according to the mutation status of BRAF and K-ras, and that samples with the BRAF-V600E and non-V600E mutants could be distinguished from each other by gene profiling. Examination of TNM-Duke's staging, MSI and mutations in APC and TP53 revealed that these significant mutations could not account for the hierarchical clustering results observed in our study. We herein identified distinct gene expression patterns and gene sets that may form the basis for identification of BRAF-targeting molecules or provide researchers with a better understanding of the molecular pathogenesis underlying RAS-RAF signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219636     DOI: 10.1093/carcin/bgi237

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  12 in total

1.  Mycobacterial bacilli are metabolically active during chronic tuberculosis in murine lungs: insights from genome-wide transcriptional profiling.

Authors:  Adel M Talaat; Sarah K Ward; Chia-Wei Wu; Elizabeth Rondon; Christine Tavano; John P Bannantine; Rick Lyons; Stephen A Johnston
Journal:  J Bacteriol       Date:  2007-03-23       Impact factor: 3.490

2.  Development and applications of a BRAF oligonucleotide microarray.

Authors:  Il-Jin Kim; Hio Chung Kang; Sang Geun Jang; Sun-A Ahn; Hyun-Ju Yoon; Jae-Gahb Park
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

Review 3.  Predictive and prognostic markers in colorectal cancer.

Authors:  Ben George; Scott Kopetz
Journal:  Curr Oncol Rep       Date:  2011-06       Impact factor: 5.075

4.  The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.

Authors:  Ismail Beypinar; Hacer Demir; Abdullah Sakin; Burcu Yapar Taskoylu; Teoman Sakalar; Yakup Ergun; Mustafa Korkmaz; Ozturk Ates; Tulay Eren; Serdar Turhal; Mehmet Artac
Journal:  J Gastrointest Cancer       Date:  2021-09

5.  Mechanisms of aneuploidy induction by RAS and RAF oncogenes.

Authors:  Tamihiro Kamata; Catrin Pritchard
Journal:  Am J Cancer Res       Date:  2011-03-29       Impact factor: 6.166

6.  Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network.

Authors:  Bi-Qing Li; Tao Huang; Lei Liu; Yu-Dong Cai; Kuo-Chen Chou
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

7.  BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.

Authors:  T Yokota; T Ura; N Shibata; D Takahari; K Shitara; M Nomura; C Kondo; A Mizota; S Utsunomiya; K Muro; Y Yatabe
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

Review 8.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

9.  Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.

Authors:  Hiraku Itadani; Shinji Mizuarai; Hidehito Kotani
Journal:  Curr Genomics       Date:  2008       Impact factor: 2.236

10.  Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.

Authors:  Petra Grbčić; Dora Fučkar Čupić; Tania Gamberi; Sandra Kraljević Pavelić; Mirela Sedić
Journal:  Int J Mol Sci       Date:  2021-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.